SCHEMBL13019

SCHEMBL13019

C1CCN(CCN2CCOCC2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
KEAP1 Q14145 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
ALDH1A1 P00352 1/20 0.56
GLA P06280 1/20 0.50
HRH3 Q9Y5N1 6/20 0.48
USP2 O75604 1/20 0.46
HPGD P15428 1/20 0.45
DUSP3 P51452 1/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
POLB P06746 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
HSD17B10 Q99714 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
PRMT8 Q9NR22 1/20 0.42
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12937 0.97 ALDH1A1 (0.54) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA
SCHEMBL14385507 0.94 KDM4E (0.56) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA
SCHEMBL4042395 0.92 KEAP1 (0.62) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA
SCHEMBL17377315 0.92 KEAP1 (0.62) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA
SCHEMBL235080 0.90 KDM4E (0.65) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA
SCHEMBL30596603 0.89 SMN1; SMN2 (0.60) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA
SCHEMBL13334891 0.89 KEAP1 (0.48) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA
SCHEMBL22048302 0.87 HRH3 (0.71) KDM4EKEAP1SMN1; SMN2ALDH1A1HRH3
SCHEMBL463276 0.87 KDM4E (0.78) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA
SCHEMBL10913328 0.87 KDM4E (0.70) KDM4EKEAP1SMN1; SMN2ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016020201-A1 NITROGEN-CONTAINING COMPOUNDS SUITABLE FOR USE IN THE PRODUCTION OF POLYURETHANES EVONIK DEGUSSA GMBH (DE) 2016-02-11 WO claimed
EP-2506716-B1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2017-05-17 EP disclosed
WO-2016020201-A1 NITROGEN-CONTAINING COMPOUNDS SUITABLE FOR USE IN THE PRODUCTION OF POLYURETHANES EVONIK DEGUSSA GMBH (DE) 2016-02-11 WO disclosed
US-20120238545-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO SA (CH) 2012-09-20 US disclosed
WO-2011058149-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO S.A. (CH) 2011-05-19 WO disclosed
US-20070043010-A1 Quinazoline derivatives ASTRAZENECA UK LIMITED (GB) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238545-A1 TRICYCLIC PYRAZOL AMINE DERIVATIVES PI4KB, MTOR, PI4KA KDM4E 1093/4885KEAP1 1326/4885SMN1; SMN2 2692/4885
US-20070043010-A1 Quinazoline derivatives ERBB2, ABL1, EGFR KDM4E 2957/4885KEAP1 1006/4885SMN1; SMN2 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.